Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
izicopan
- Development stage
- Phase 1
- Lead developer
- InflaRx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Izicopan (formerly known as INF904) is an orally administered small molecule inhibitor of the C5a receptor 1 (C5aR1), also known as the C5a anaphylatoxin chemotactic receptor. Developed by InflaRx, it targets the complement system to provide anti-inflammatory therapeutic effects by blocking C5a-induced neutrophil activation. The drug is currently in Phase 2 clinical development for inflammatory and immunological (I&I) diseases, with a primary focus on hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). Izicopan has demonstrated a favorable safety profile in clinical studies, showing high potency with ≥90% blockade of C5a-induced neutrophil activation and minimal CYP3A4/5 enzyme inhibition without hepatotoxicity signals. The World Health Organization granted the international nonproprietary name 'izicopan' in December 2025.
- Brand names
- izicopan
- Other names
- izicopan
02
Targets
C5AR1 (Complement C5a receptor 1)
Beyond the preview
Go deeper on izicopan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on izicopan.